{"slug":"api-magentlab-com-api-calc-mrecist-c3e35c","title":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions","host":"api.magentlab.com","method":"POST","resource":"https://api.magentlab.com/api/calc/mrecist","category":"other","description":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; ","price_listed":0.005,"price_asked":0.007,"state":"overcharges","state_label":"Asked 1.4x its listed price for its own example","checks_7d":1,"answered_7d":1,"latency_ms_median":283,"reported_calls_30d":0,"reported_payers_30d":0,"networks":["eip155:8453"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"body":{"items":[{"enhancement_disappeared":true,"new_lesion":false,"viable_sum_increase_ge_20":false,"viable_sum_reduction_ge_30":false},{"enhancement_disappeared":true,"new_lesion":false,"viable_sum_increase_ge_20":false,"viable_sum_reduction_ge_30":false}]},"method":"POST","type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"body":{"additionalProperties":false,"properties":{"items":{"items":{"properties":{"enhancement_disappeared":{"description":"Disappearance of any intratumoral arterial enhancement in all target lesions, as assigned by the caller (Lencioni 2010 mRECIST CR). true or false. magent does not measure arterial-phase enhancement or read CT/MRI.","type":"boolean"},"new_lesion":{"description":"One or more new lesions as assigned by the caller (Lencioni 2010 mRECIST PD). true or false. When true, mrecist is PD regardless of enhancement or viable-sum flags. magent does not read imaging.","type":"boolean"},"viable_sum_increase_ge_20":{"description":"≥20% increase in the sum of diameters of viable (arterial-enhancing) target lesions versus nadir, as assigned by the caller (Lencioni 2010 mRECIST PD). Do not also require a 5 mm absolute increase. true or false. magent does not measure lesions.","type":"boolean"},"viable_sum_reduction_ge_30":{"description":"≥30% decrease in the sum of diameters of viable (arterial-enhancing) target lesions versus baseline, as assigned by the caller (Lencioni 2010 mRECIST PR). true or false. magent does not measure lesions.","type":"boolean"}},"required":["new_lesion","viable_sum_increase_ge_20","enhancement_disappeared","viable_sum_reduction_ge_30"],"type":"object"},"maxItems":25,"minItems":1,"type":"array"}},"required":["items"],"type":"object"},"headers":{"additionalProperties":{"type":"string"},"type":"object"},"method":{"const":"POST","type":"string"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-09-28","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.007,"price_match":false,"latency_ms":283,"error":null}],"description_full":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; magent does not read imaging. Not a medical device, not a diagnosis, not RECIST 1.1, not EASL necrosis-only, not the 2019 Llovet +5 mm PD refinement, and not nontarget-only overall response.","last_updated":"2026-09-28T14:06:00.32Z","schemes":["exact"]}